Literature DB >> 10023633

Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease.

R J Johnson, S D Kivlighn, Y G Kim, S Suga, A B Fogo.   

Abstract

An elevated uric acid level is associated with cardiovascular disease. Hyperuricemia is predictive for the development of both hypertension and coronary artery disease; it is increased in patients with hypertension, and, when present in hypertension, an elevated uric acid level is associated with increased cardiovascular morbidity and mortality. Serum uric acid level should be measured in patients at risk for coronary artery disease because it carries prognostic information. Hyperuricemia is caused by decreased renal excretion. In this article, we suggest that this may be mediated by intrarenal ischemia with lactate generation and the inhibition of the secretion of urate by the anion-exchange transport system. The possibility that hyperuricemia directly contributes to cardiovascular or renal disease needs to be reconsidered. Although hyperuricemia is associated with a number of cardiovascular or renal risk factors, several studies have found uric acid level to be independently associated with increased mortality by multivariate analysis. If hyperuricemia is directly toxic, the most likely site is the kidney. Chronic hyperuricemia is strongly associated with chronic tubulointerstitial disease, and many of these patients have decreased renal function. Although it is possible that the hyperuricemia could simply be the consequence of the renal disease, further studies are necessary to rule out a pathogenic role for uric acid in the development of renal disease and salt-dependent hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10023633     DOI: 10.1016/s0272-6386(99)70295-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  46 in total

Review 1.  Serum uric acid is not an independent risk factor for coronary heart disease.

Authors:  S G Wannamethee
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

Review 2.  Pathogenesis of hyperuricemia: recent advances.

Authors:  Manisha Ghei; Mihaela Mihailescu; Dennis Levinson
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

Review 3.  The long-term renal and cardiovascular consequences of prematurity.

Authors:  Carolyn L Abitbol; Maria M Rodriguez
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

4.  Characterization and Activation of NLRP3 Inflammasomes in the Renal Medulla in Mice.

Authors:  Min Xia; Justine M Abais; Saisudha Koka; Nan Meng; Todd W Gehr; Krishna M Boini; Pin-Lan Li
Journal:  Kidney Blood Press Res       Date:  2016-03-25       Impact factor: 2.687

5.  Genotype-based changes in serum uric acid affect blood pressure.

Authors:  Afshin Parsa; Eric Brown; Matthew R Weir; Jeffrey C Fink; Alan R Shuldiner; Braxton D Mitchell; Patrick F McArdle
Journal:  Kidney Int       Date:  2011-12-21       Impact factor: 10.612

Review 6.  Uric acid and chronic kidney disease: which is chasing which?

Authors:  Richard J Johnson; Takahiko Nakagawa; Diana Jalal; Laura Gabriela Sánchez-Lozada; Duk-Hee Kang; Eberhard Ritz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

7.  Calcium oxalate stone and gout.

Authors:  Y M Fazil Marickar
Journal:  Urol Res       Date:  2009-09-25

8.  Clinical study on treatment of hyperuricaemia by retention enema of Chinese herbal medicine combined with allopurinol.

Authors:  Qian Chen; Li Ma; Wupu Akebaier
Journal:  Chin J Integr Med       Date:  2010-01-18       Impact factor: 1.978

9.  Rasburicase improves hyperuricemia in infants with acute kidney injury.

Authors:  David J Hobbs; Julia M Steinke; Jin Y Chung; Gina-Marie Barletta; Timothy E Bunchman
Journal:  Pediatr Nephrol       Date:  2009-11-21       Impact factor: 3.714

Review 10.  Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection.

Authors:  Bernard Waeber; François Feihl; Luis M Ruilope
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.